PubMed Health⌕ Search

PubMed · 2695215

Technical introduction to nuclear imaging.

Abstract

It is very important to pay attention to technical detail when acquiring nuclear scans of the heart. It must be remembered that not only is the heart a three dimensional structure, which imposes its own limitations on the interpretation of information represented as two dimensional images, but the organ also moves which will in turn degrade static images. Dynamic studies of left ventricular function must be able to resolve the rapidly changing events of the cardiac cycle which makes specific technical demands upon the imaging equipment and computer system used. In spite of these potential drawbacks, both static and dynamic imaging of the heart using radiopharmaceuticals are widely used in a clinical and research environment. In this article some of the technical considerations will be covered as they apply to both the commonly used clinical applications of nuclear cardiology and some of the newer but potentially exciting techniques will also be covered briefly.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D S Dymond. 1989. Technical introduction to nuclear imaging.. https://doi.org/10.1093/oxfordjournals.bmb.a072370

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.

The peroxisome proliferator-activated receptor (PPAR) family of genes plays a major role in metabolic regulation. Unfortunately, the results of two recent, large event trials of PPAR agonists have been mixed. High rates of crossover to statin use confound the interpretation of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, which found a less than expected reduction in coronary and stroke events with fenofibrate. Of concern, nonsignificant increases in coronary and sudden deaths, thrombotic events, and pancreatitis occurred in the fenofibrate group. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROACTIVE) also found a reduction in coronary and stroke events with pioglitazone compared with placebo in a population with diabetes and cardiovascular disease, but this benefit was counterbalanced by an increase in congestive heart failure as well as symptomatic edema. Further research is needed to determine the role of PPAR agonists in the prevention of cardiovascular disease.

Coronary Disease↗

Depressive symptoms and sex affect completion rates and clinical outcomes in cardiac rehabilitation.

Symptoms of depression are often seen in patients with coronary heart disease. Symptoms appear more commonly in women and are negatively associated with measures of cardiovascular health. Using multiple logistic regression analyses, the authors evaluated the independent effects of depression (as measured by the Beck Depression Inventory [BDI-II]) and sex on cardiac rehabilitation (CR) completion. In addition, in those who completed CR, the authors evaluated whether depressive symptoms and sex affected clinical outcomes. Women as well as participants with enrollment BDI-II scores > or =14 had significantly higher rates of CR noncompletion. Patients with BDI-II scores > or =14 who completed CR achieved significant improvements in lipid profile, body mass index, and exercise capacity regardless of sex. Women and individuals with BDI-II scores > or =14 are at risk for CR noncompletion and should be encouraged to complete CR, because cardiovascular benefits comparable to those seen in men and individuals with low BDI-II scores were achieved when these patients completed the CR program.

Coronary Disease↗